http://www.biospace.comBioSpace RSS GeneratorWed, 19 Jun 2013 09:56:08 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2011http://www.unquote.com/benelux/news/2272881/vcbacked-cardio3-announces-ipo-plansStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Belgian heart drug specialist Cardio3 BioSciences is planning a stock market flotation in Brussels and Paris, it said on Tuesday, without giving details on the timing or size of the issue.The company, a...Wed, 05 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=296820&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Minneapolis, MN, May 14, 2013 BioAmber Inc. (BioAmber) (NYSE: BIOA.U),announced today the closing of its initial public offering of 8,000,000 units consisting of one shareof common stock and one warrant...Wed, 15 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=294604&full=1CAMBRIDGE, Mass.</span>, <span class"xn-chron">April 26, 2013</span> /PRNewswire/ -- Epizyme, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined.</p...Fri, 26 Apr 2013 12:00:00 AM GMThttp://www.streetinsider.com/IPOs/Epizyme+(EPZM)+Files+$69M+IPO/8262725.htmlEpizyme, a biotech developing therapeutics for patients with genetically defined cancers, filed on Thursday with the SEC to raise up to $69 million in an initial public offering. The company recently entered into a collaboration agreement with Abbott Laboratories to develop a diagnostic to detect which patients would qualify for Epizyme's product candidates. The Cambridge, MA-based company, which was...Mon, 22 Apr 2013 12:00:00 AM GMThttp://www.bizjournals.com/sanfrancisco/blog/biotech/2013/04/portola-pharmaceuticals-ipo-ptla.html<div id"releaseBody"><p>SOUTH SAN FRANCISCO, CA--(Marketwired - April 12, 2013) - <b> </b>Portola Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been...Mon, 15 Apr 2013 12:00:00 AM GMThttp://www.fiercebiotech.com/story/biotech-chimerix-shines-ipo-debut-interest-grows-antiviral-drugs/2013-04-12Chimerix sped out of the IPO gate on Thursday. The Durham, NC-based drug developer's ($CMRX) stock soared on its first day of trading, with an initial price of $14 per share that shot up 34% to $18.79 per share by the end of the day. The stellar start followed optimism on Wall Street about the biotech's pipeline of antiviral therapies with big sales potential. As The News & Observer reported, Chimerix...Fri, 12 Apr 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130410by Richard Daverman, PhD</p><p>April 10, 2013 -- Tong Ren Tang Technologies Co., a maker of Traditional Chinese Medicines, is moving forward on its long-term plan to spin off and IPO a subsidiary, TRT Chinese Medicine, on the ChiNext exchange, probably within the next three months. TRT Chinese Medicines is Chinas largest exporter of TCM products. Details of the offering are not yet available...Thu, 11 Apr 2013 12:00:00 AM GMThttp://www.nasdaq.com/article/biotech-company-chimerix-sets-terms-for-85-million-ipo-cm232282#.UVruTTeKCE8Chimerix, a biopharmaceutical company developing oral antiviral therapeutics for CMV, announced terms for its IPO on Monday. The Durham, NC-based company plans to raise $85 million by offering 6.1 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Chimerix would command a market value of $325 million.Tue, 02 Apr 2013 12:00:00 AM GMThttp://www.bizjournals.com/boston/blog/bioflash/2013/03/tetraphase-enanta-prepare-for-ipos.html?ana=otjTwo Boston-area biotech companies one working on a treatment for hepatitis C, the other aimed at drugs to treat disease caused by bacterial biothreat pathogens are set to raise a combined total of $146 million through two initial public offerings during the week starting March 18. According to Renaissance Capital, Enanta Pharmaceuticals Inc. in Watertown, Mass., and Tetraphase Pharmaceuticals Inc...Tue, 19 Mar 2013 12:00:00 AM GMThttp://www.bloomberg.com/news/2013-03-11/veeva-said-to-plan-ipo-as-cloud-startup-challenges-oracle.htmlPharmaceutical sales software developer Veeva Systems is reportedly planning an IPO this year that could give it a $2 billion valuation. Bloomberg cited unnamed sources who said the Pleasanton-based company led by co-founder and CEO Peter Gassner is meeting with banks. Gordon Ritter of Emergence Capital Partners, whose firm backed Veeva and is on the company's board, told Bloomberg that the company...Tue, 12 Mar 2013 12:00:00 AM GMThttp://online.wsj.com/article/SB10001424127887324329204578270481679844370.htmlBausch & Lomb Inc.'s private-equity owners are leaning toward launching an initial public offering of shares in the eye-health company after possible buyers of the business balked at the asking price of at least $10 billion, according to people familiar with the matter. Warburg Pincus LLC, which owns Bausch & Lomb, has fielded interest from five potential buyers of the business and asked for initial...Tue, 29 Jan 2013 12:00:00 AM GMThttp://www.reuters.com/article/2013/01/25/us-quintiles-ipo-idUSBRE90O14420130125Quintiles Transnational Corp, the largest provider of contract research for the pharmaceutical and biotechnology industries, is speaking to banks about a potential initial public offering, two people familiar with the matter said on Friday. Quintiles has held "bake-off" talks with banks this week to appoint bookrunners for an IPO, the people said on condition of anonymity because the discussions are...Mon, 28 Jan 2013 12:00:00 AM GMThttp://www.streetinsider.com/IPOs/Pfizers+Zoetis+(ZTS)+Sees+IPO+Price+of+$22+-+$25Share/8016789.htmlPfizer Inc's unit Zoetis Inc plans to sell 86.1 million shares at between $22 and $25 each in an initial public offering that could value the animal health business at as much as $12.5 billion. At the top-end of the expected range, the offering would raise about $2.2 billion. The Wall Street Journal reported last month that the Zoetis IPO was likely by January or February, and that it could raise about...Mon, 21 Jan 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130115by Richard Daverman, PhD</p><p>January 14, 2013 -- China National Biotech, the largest biotech in China, is once again reported to be planning a Hong Kong IPO, though the company has not made a formal announcement of the transaction. According to sources, the IPO will raise $1.5 billion. The tentative scheduling is for CNBG to file by the end of March, with the actual transaction taking place in...Tue, 15 Jan 2013 12:00:00 AM GMThttp://www.streetinsider.com/IPOs/Pfizer+(PFE)+Said+to+Plan+IPO+of+Animal-Health+Unit+in+Early+FY13/7948093.htmlPfizer Inc's planned U.S. initial public offering (IPO) of its animal-health unit Zoetis Inc is likely by January or February and raise about $4 billion, the Wall Street Journal reported, citing people familiar with the discussions. The sources told the paper a final decision on the offering would depend on market conditions. The largest U.S. drug-maker believed that an IPO is the way to go for Zoetis...Fri, 14 Dec 2012 12:00:00 AM GMThttp://www.healthcareglobal.com/finance_insurance/quintiles-transnational-corp-plans-to-file-for-ipo-in-18-mthsQuintiles Transnational Corp., the biggest provider of testing and drug-trial services to pharmaceutical companies, is studying an initial public offering, said two people familiar with the situation. The company may file for the IPO in the next 18 months, said one of the people, who asked not to be identified because the talks are private. Quintiles was bought in 2008 by private- equity firms including...Tue, 25 Sep 2012 12:00:00 AM GMThttp://www.xconomy.com/boston/2012/08/30/ovascience-founded-by-sirtris-vets-plans-ipo/Boston-based OvaScience, which is developing infertility treatments based on stem cell science, filed documents with the SEC announcing its plans to go public. According to the filing, the company intends to sell 7.6 million shares and trade on the over-the-counter exchange. OvaScience was founded on technology developed at Harvard Medical School and Massachusetts General Hospital, which the company...Thu, 30 Aug 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120526by Richard Daverman, PhD</p><p>May 25, 2012 -- Yantai Dongcheng Biochemicals has completed a $110 million IPO on Shenzhens Small and Medium-Sized Enterprises Board. The main products from Dongcheng Biochemicals, which makes APIs and finished products, are heparin sodium and chondroitin sulphate, a dietary supplement that treats osteoarthritis. More details....</p><p>Stock Symbol: (SHE: 0...Tue, 29 May 2012 12:00:00 AM GMThttp://www.bizjournals.com/washington/news/2012/05/04/supernus-moves-from-ipo-to-fda.htmlROCKVILLE, Md., May 4, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN - News) (the "Company"), today announced the closing of its initial public offering of 10,000,000 of its common stock at a price of $5.00 per share. The Company's shares are listed on The NASDAQ Global Market under the trading symbol "SUPN." After underwriting discounts and commissions and estimated offering...Mon, 07 May 2012 12:00:00 AM GMThttp://www.mlive.com/business/west-michigan/index.ssf/2012/04/report_pfizer_may_use_ipo_shar.htmlPfizer Inc. (PFE) (PFE) is likely to divest its animal health unit through a combination of an initial public offering and an exchange of shares with current stockholders, Chief Executive Officer Ian Read said. Were probably going to exchange, part of it will be sold for stock in the open market, part of it will be swapped for Pfizer shares, Read said today at the companys annual investor meeting...Mon, 30 Apr 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120208_1February 8, 2012 -- Shanghai Fosun Pharma's on-again/off-again Hong Kong IPO is apparently now scheduled to take place early this year. According to an unnamed insider, the company has filed its listing application with the Hong Kong exchange. Fosun hopes to raise between $600 million and $800 million by floating up to a 20% stake in the company. More details....</p><p>Stock Symbol: (SHA: 600...Thu, 09 Feb 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20111205_1December 5, 2011 -- Lanzhou Foci Pharma will issue 20.2 million shares in its IPO on the Shenzhen Small and Medium Enterprise Exchange. The expected date is December 13th. The new shares will comprise 25% of the companys post-IPO capitalization of 80.8 million shares. Founded in Shanghai in 1929, Foci Pharma mainly sells and distributes patented TCMs, although it also deals in western drugs and raw...Tue, 06 Dec 2011 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20111104_1November 4, 2011 -- China National Biotechnology Group (CNBG) plans a Hong Kong IPO, according to Zhiping Song, Chairman of its parent, China National Pharmaceutical Group Corporation (SinoPharm Group). CNBG, which will change its name to China Biotech, is comprised of six institutes of biological products. So far, no predictions of the size of the offering have been published. More details....Mon, 07 Nov 2011 12:00:00 AM GMThttp://www.chicagobusiness.com/article/20110726/NEWS03/110729911/horizon-pharma-joins-ipo-parade#ixzz1TDESmucLA Northbrook-based biopharmaceutical startup is expected to go public this week with a $61-million stock offering. Horizon Pharma Inc., which is developing new drugs for arthritis and pain, is offering 5.5 million shares that are expected to be priced between $10 to $12 each as soon as Wednesday, according to gaskinco.com, a website by financial analyst Francis Gaskins that tracks IPOs. The stock offering...Tue, 26 Jul 2011 12:00:00 AM GMThttp://www.reuters.com/article/2011/07/12/novartis-china-ipo-idUSL3E7IB16L20110712Swiss drugmaker Novartis AG could soon be in the position to go for deals again after its $51 billion buy of U.S.-listed eyecare group Alcon, the group's chief executive was quoted as saying on Monday. CEO Joe Jimenez said paying down Novartis' debt of $22 billion was the group's first priority but that it should be able to do this quickly thanks to its strong cash flow. "We could soon be in the position...Tue, 12 Jul 2011 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20110622_1June 22, 2011 -- Shandong Jincheng Pharmaceutical and Chemical completed a 465 million RMB ($72 million) IPO on Shenzhens GEM exchange. The company issued 25 million shares at 18.6 yuan each, a price that reflects a P/E ratio of 22.7. Jincheng Pharma makes cephalosporin intermediates. It plans to use the proceeds of the offering to expand its production capacity. More details....</p><p>Stock Symbol...Wed, 22 Jun 2011 12:00:00 AM GMThttp://www.xconomy.com/san-diego/2011/06/08/ambit-withdraws-ipo/San Diegos Ambit Biosciences, which is developing anti-cancer compounds that block the activity of certain protein kinases, withdrew its IPO registration, according to a regulatory filing yesterday. The biotech filed to go public on Nov. 5, and had planned to raise more than $86 million. In a letter signed by CFO Alan Fuhrman, Ambit says the initial public offering would have been a discretionary...Thu, 09 Jun 2011 12:00:00 AM GMThttp://www.xconomy.com/detroit/2011/06/02/so-close-they-can-taste-it-nanobio-investors-eye-potential-ipo/Is NanoBio heading towards an IPO?</p><p>Probably way too early to make that call. But the Ann Arbor, MI-based drug startup and its investors are not exactly discouraging such talk.</p><p>I think the company has the potential to be a public company, says George Arida, a managing director of Venture Investors. It absolutely has the breadth [of potential products] to do that. Its not too...Fri, 03 Jun 2011 12:00:00 AM GMThttp://www.xconomy.com/boston/2011/05/31/myriant-technologies-files-for-125m-ipo/ Myriant Technologies, a Quincy, MA-based developer of biochemicals, revealed its intention to raise $125 million in an initial public offering, according to documents filed with the SEC. The company plans to put the proceeds toward completing a plant in Louisiana, as well as working capital, research and development, and general corporate purposes. It reported a $16 million net loss on $14 million...Wed, 01 Jun 2011 12:00:00 AM GMThttp://www.rttnews.com/Content/BreakingNews.aspx?Node=B1&Id=1633885Algae-based biofuel company Solazyme Inc. has upped its IPO price to $18 a share.</p><p>The maker of renewable oil and bioproducts had earlier estimated a share price of $15 to $17 for its initial public offering.</p><p>South San Francisco-based Solazyme and its shareholders will offer about 10.9 million shares of its common stock, and underwriters are granted a 30-day option to purchase up...Fri, 27 May 2011 12:00:00 AM GMThttp://www.streetinsider.com/IPOs/Advanced+Biohealing+%28ABHB%29+Sees+IPO+Price+of+$14+-+$16Share/6476647.htmlAdvanced Biohealing Inc, a regenerative drug maker, said it would price its initial public offering at $14-$16 per share and expects to raise about $200 million.</p><p>Of the total 13.4 million shares, the company will sell 8.4 million, while the rest will be offered by selling stockholders, it said in a regulatory filing.</p><p>The Westport, Connecticut-based company posted revenue of $1...Fri, 06 May 2011 12:00:00 AM GMThttp://www.reuters.com/article/2011/05/03/us-shanghaipharmaipo-idUSTRE74217L20110503Bloomberg -- Shanghai Pharmaceuticals Holding Co., Chinas second-largest drug distributor, will sell new shares to Temasek Holdings Pte and Pfizer Inc. (PFE) in an offering in Hong Kong of as much as $2.2 billion of stock to fund acquisitions.</p><p>Temasek, a Singapore state investment company, Pfizer, Guoco Group and Bank of China Group Investment will buy a total of $550 million shares for...Tue, 03 May 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=218375&full=1SCHAUMBURG, Ill., April 26, 2011 /PRNewswire/ -- Sagent Pharmaceuticals, Inc. (the "Company") (Nasdaq:SGNT - News) today announced that it has closed its previously announced initial public offering of 5,750,000 shares of its common stock at a price to the public of $16.00 per share. In connection with the initial public offering, the underwriters exercised in full their option to purchase an additional...Wed, 27 Apr 2011 12:00:00 AM GMThttp://www.streetinsider.com/IPOs/Sagent+Pharmaceuticals+%28SGNT%29+Prices+Up-Sized+Offering+at+%2416%2C+High+End+of+Range/6439007.htmlSCHAUMBURG, Ill., April 20, 2011 /PRNewswire/ -- Sagent Pharmaceuticals (Nasdaq:SGNT - News) announced the upsizing and pricing of its initial public offering. The size of the offering has been increased from the previously announced 5,000,000 shares of common stock to 5,750,000 shares of common stock at a price to the public of $16.00 per share. The shares are scheduled to begin trading on The NASDAQ...Wed, 20 Apr 2011 12:00:00 AM GMThttp://www.renaissancecapital.com/ipohome/news/Sagent-Pharmaceuticals-reveals-IPO-terms-9301.htmlSCHAUMBURG, Ill.</span>, <span class"xn-chron">April 6, 2011</span> /PRNewswire/ -- Sagent Pharmaceuticals (the "Company"), announced that it has commenced an initial public offering of 5,000,000 shares of common stock. </p><p>The estimated range for the initial public offering price is <span class"xn-money">$14.00 to $16.00</span> per share. The Company has applied to list its common stock on...Wed, 06 Apr 2011 12:00:00 AM GMThttp://www.medcitynews.com/2011/04/stem-cell-therapy-firm-aldagen-withdraws-plans-for-80m-ipo/ Triangle Business Journal -- Aldagen Inc. has withdrawn its long-awaited $80.5 million IPO.</p><p>The Durham-based drug developer filed the withdrawal request with regulators on Tuesday, citing market conditions and its determination that registration of the companys securities is not in the best interest of the company at this time.</p><p>Aldagen had filed an S-1 to go public in October...Wed, 06 Apr 2011 12:00:00 AM GMThttp://www.wiredvc.com/tranzyme-pharma-prices-ipo-at-4-per-share-set-to-raise-54m/RESEARCH TRIANGLE PARK, N.C., April 1, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM - News) announced today the pricing of its initial public offering of 13,500,000 shares of its common stock at $4.00 per share. The shares are expected to begin trading on Monday, April 4, 2011 on The NASDAQ Global Market under the ticker symbol "TZYM." All of the shares in the offering are being offered by...Mon, 04 Apr 2011 12:00:00 AM GMThttp://online.wsj.com/article/SB10001424052748703806304576232560144660964.html?mod=dist_smartbriefWSJ -- Appetite for Israeli initial public offerings of life-science companies is booming, but critics say the sector is immature and lacks the transparency for investors to make informed decisions.</p><p>The first three months of 2011 have brought four life-sciences IPOs, and several more are planned for the first half of the year. The rate so far has been far ahead of that of the past three years...Fri, 01 Apr 2011 12:00:00 AM GMThttp://www.pehub.com/98666/solazyme-files-for-100m-ipo/GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--On March 11, 2011, one of Keating Capital, Inc.s portfolio companies, Solazyme, Inc., filed an S-1 registration statement to go public through a $100 million initial public offering of its common stock. Solazyme intends to list its shares on the Nasdaq Global Market under the symbol "SZYM." Morgan Stanley and Goldman, Sachs & Co. are acting as lead underwriters...Tue, 15 Mar 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=211379&full=1<div id"releaseBody"><p>PHILADELPHIA, PA and REHOVOT, ISRAEL--(Marketwire - February 22, 2011) - <b>Rosetta Genomics, Ltd. </b>(NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerROSG">ROSG</a>) today announced the closing of an initial public offering (IPO) of its majority-owned subsidiary, Rosetta Green, in Israel which raised gross proceeds of 21,900,960 NIS ($6.06 million). Shares...Tue, 22 Feb 2011 12:00:00 AM GMThttp://www.pharmatimes.com/Article/11-02-15/Philogen_IPO_pulled_as_Bayer_exits_cancer_pact.aspxPharma Times -- An eagerly-anticipated initial public offering by the Swiss-Italian biotech Philogen has been cancelled at the last minute after partner Bayer pulled out of their oncology collaboration.Tue, 15 Feb 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=210439&full=1REDWOOD CITY, Calif.</span>, <span class"xn-chron">Feb. 11, 2011</span> AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the pricing of its initial public offering of 8 million shares of common stock at <span class"xn-money">$...Fri, 11 Feb 2011 12:00:00 AM GMThttp://www.reuters.com/article/2011/02/08/philogen-ipo-idUSLDE7171XP20110208ZURICH, Feb 8 (Reuters) - Swiss-Italian biotech group Philogen said it plans to debut on the Milan stock exchange later this month, in Europe's first biotech initial public offering in 2011 and the latest sign appetite for the sector is warming.Thu, 10 Feb 2011 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20110209007078&newsLang=enWALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine (NASDAQ: BGMD) today announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicines common stock at $7.00 per share, less underwriting discounts and commissions. BG Medicine also announced that it has closed its initial public offering of 5,750,...Thu, 10 Feb 2011 12:00:00 AM GMThttp://www.globenewswire.com/newsroom/news.html?d=213312WEST LAFAYETTE, Ind., Feb. 9, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates and companion imaging diagnostics for personalized therapy, announced today the closing of its initial public offering of 14,375,000 shares of common stock (including 1,875,000 shares of common stock pursuant to the exercise of the over...Wed, 09 Feb 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=209758&full=1FRANKLIN, Tenn.</span>, <span class"xn-chron">Feb. 4, 2011</span> /PRNewswire/ -- MedQuist Holdings Inc. [Nasdaq: MEDH], formerly CBaySystems Holdings Limited, a leading provider of integrated clinical documentation solutions for the U.S. Healthcare system, today announced the pricing of its U.S. initial public offering of 4,500,000 shares of its common stock at a price to the public of <span class...Mon, 07 Feb 2011 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20110207006348&newsLang=enTEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd., an Israeli biopharmaceutical company, announced today the successful completion of the Companys initial public offering (IPO), of shares and warrants, on the Tel-Aviv Stock Exchange (TASE). The Company raised NIS 51.6 million (approximately $13.6 million). Mon, 07 Feb 2011 12:00:00 AM GMThttp://www.thestreet.com/story/10997275/1/endocyte-inc-announces-pricing-of-initial-public-offering.htmlFeb. 4 (Bloomberg) -- Endocyte Inc., a developer of drugs for ovarian and lung tumors, raised $75 million in its initial public offering after cutting the price twice this week for a total reduction of as much as 60 percent.Fri, 04 Feb 2011 12:00:00 AM GMThttp://www.xconomy.com/san-diego/2011/02/03/pacira-raises-42m-in-ipo/Wall Street Journal -- Pacira Pharmaceuticals Inc. generated little interest among investors on its first day of trading Thursday, even after it cut its offering price in half.The company's stock opened at $7 a share on the Nasdaq, flat with its initial public offering price. It sold six million shares, nearly two million more than expected, but at a greatly reduced price. The company had originally...Thu, 03 Feb 2011 12:00:00 AM GMThttp://www.xconomy.com/san-francisco/2011/01/21/acelrx-prices-ipo/Xconomy -- Redwood City, CA-based AcelRx Pharmaceuticals, which filed paperwork last November for an initial public offering on the Nasdaq exchange, set its IPO terms in an updated regulatory filing yesterday.Mon, 24 Jan 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=208288&full=1KUWAIT--(Marketwire - 01/20/11) - Al-Dorra Holdings, a privately held Kuwaiti company, announced today the intent to IPO its newly formed subsidiary Hail First Pharma Inc. in the first quarter of this year.</p><p>According to the company, Hail First Pharma Inc. is the result of several acquisitions and or joint-ventures with international pharmaceutical companies including but not limited to Spencer...Fri, 21 Jan 2011 12:00:00 AM GMThttp://www.bloomberg.com/news/2010-12-17/ventrus-biosciences-prices-ipo-at-6-per-share.htmlNEW YORK, Dec. 16, 2010 (GLOBE NEWSWIRE) -- Ventrus Biosciences Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its initial public offering of 2,900,000 shares at $6.00 per share. The shares are expected to begin trading tomorrow, December 17, 2010 on the Nasdaq Capital Market under the symbol...Fri, 17 Dec 2010 12:00:00 AM GMThttp://www.xconomy.com/boston/2010/12/10/bg-medicine-reveals-ipo-plans/Boston Business Journal - by Kyle Alspach -- BG Medicine Inc. is expected to announce an initial public offering of up to $71.2 million next week, according to IPO tracker Renaissance Capital.<p></p>The Waltham, Mass.-based developer of biomarker-based diagnostic tools is expected to price the roughly 4.7 million shares in the range of $13 to $15, according to Renaissance Capital. BG Medicine is...Mon, 13 Dec 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=203941&full=1PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC - News) today announced the completion of its initial public offering of 12,000,000 shares of its common stock at a price of $5.00 per share. In addition, Anacor has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of its common stock at the initial public offering price, less the...Wed, 01 Dec 2010 12:00:00 AM GMThttp://www.forbes.com/feeds/ap/2010/11/24/business-health-care-us-anacor-ipo-pricing_8161577.htmlPALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price of $5.00 per share. The common stock is expected to begin trading on the NASDAQ Global Market today under the trading symbol ANAC. Anacor has granted the underwriters a 30 day option to purchase up to an additional 1,800...Wed, 24 Nov 2010 12:00:00 AM GMThttp://www.bloomberg.com/news/2010-11-23/china-xiniya-zogenix-raise-144-million-combined-in-u-s-ipos.htmlSAN DIEGO, Nov. 22, 2010 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX - News) announced today the pricing of its initial public offering of 14,000,000 shares of its common stock at $4.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Zogenix. In addition, the underwriters have a 30-day option to purchase up to an additional 2,1...Tue, 23 Nov 2010 12:00:00 AM GMThttp://www.scripintelligence.com/business/Clarus-files-for-86M-IPO-as-cash-run-dries-306373DOW JONES NEWSWIRES -- Clarus Therapeutics Inc. has filed plans to sell up to an estimated $86.3 million in shares in an initial public offering. The pharmaceutical company has applied for its shares to be traded on the Nasdaq Global Market under the symbol CLRS. Clarus, which is developing an oral testosterone replacement therapy called OriTex, plans to use proceeds from the IPO to pay for a Phase...Tue, 23 Nov 2010 12:00:00 AM GMThttp://www.scripintelligence.com/business/Indias-Claris-plans-66-million-IPO-306371Economic Times -- Ahmedabad-based critical care and hospital products maker, Claris Lifesciences Ltd , has finally received approval from Securities and Exchange Board of India (SEBI) for its maiden public issue to raise Rs 300 crore. Tue, 23 Nov 2010 12:00:00 AM GMThttp://www.reuters.com/article/idCNTOE6AB09820101112?rpc=44TOKYO, Nov 12 (Reuters) - Japanese drugmaker Otsuka Holdings plans to sell about $2.8 billion worth of shares in December, marking the world's largest initial public offering in the pharmaceuticals sector.Fri, 12 Nov 2010 12:00:00 AM GMThttp://www.xconomy.com/san-francisco/2010/11/10/complete-genomics-gets-ho-hum-reception-cuts-ipo-price-more-than-30-percent-to-9/Silicon Valley / San Jose Business Journal -- Complete Genomics Inc. raised about $54 million in its initial public offering, after the company's shares sold below the price range the company had expected.<p></p>Mountain View-based Complete Genomics sold 6 million shares priced at $9 per share, below the $12 to $14 range expected earlier.<p></p>In its regulatory filing Complete Genomics had estimated...Thu, 11 Nov 2010 12:00:00 AM GMThttp://www.reuters.com/article/idCNLDE6A82LF20101109?rpc=44NEW YORK Nov 9 (Reuters) - An HIV company set up a year ago by GlaxoSmithKline Plc (GSK.L) and Pfizer Inc (PFE.N) could be spun off and floated in an initial public offering once its drug pipeline has matured a little further.Wed, 10 Nov 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=201365&full=1<div class"xn-content"><p><span class"xn-location">SAN DIEGO</span>, <span class"xn-chron">Nov. 5, 2010</span> /PRNewswire/ -- Ambit Biosciences Corporation (Ambit), a recognized global leader in kinase drug discovery and development, announced today that it has filed a registration statement with the Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of...Mon, 08 Nov 2010 12:00:00 AM GMThttp://www.xconomy.com/san-diego/2010/11/05/zogenix-sets-ipo-range/Wall Street Journal -- Zogenix Inc. said Thursday that it expects to sell 6 million shares of its common stock at a price between $12 and $14 a share, in an initial public offering in which the company's venture investors could purchase $15 million of the company's stock.Fri, 05 Nov 2010 12:00:00 AM GMThttp://www.reuters.com/article/idUSN2616989720101026MENLO PARK, Calif., Oct 26, 2010 (BUSINESS WIRE) -- Pacific Biosciences of California, Inc. , developer of single molecule, real-time (SMRT(TM)) technology for biological analysis, announced today the pricing of its initial public offering of 12,500,000 shares of its common stock at $16.00 per share. All shares are being sold by the company. The Company is also offering its underwriters a 30-day option...Wed, 27 Oct 2010 12:00:00 AM GMThttp://www.globenewswire.com/newsroom/news.html?d=204535BRIDGEWATER, N.J., Oct. 22, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $9.50 per share, before underwriting discounts and commissions. All shares are being sold by the company. Aegerion has granted the underwriters an option for 30 days to purchase up to an additional ...Mon, 25 Oct 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=198849&full=1COPENHAGEN, Oct 21 (Reuters) - Zealand Pharma's owners are considering floating part of the Danish biotech firm on the Copenhagen bourse in November, sources said.Thu, 21 Oct 2010 12:00:00 AM GMThttp://www.reuters.com/article/idCNSGE6940GU20101005?rpc=44Reuters -- Pacific Biosciences of California Inc said it expects to raise up to $230 million in an initial public offering of its common stock.Tue, 05 Oct 2010 12:00:00 AM GMThttp://www.reuters.com/article/idCNN2726449120100928?rpc=44NEW YORK, Sept 27 (Reuters) - Amyris Inc (AMRS.O), which uses yeast to convert plant sugars into the building blocks of anti-malarial drugs, priced shares in its initial public offering below the range on Monday, according to an underwriter.Tue, 28 Sep 2010 12:00:00 AM GMThttp://www.xconomy.com/san-diego/2010/09/07/san-diegos-zogenix-files-for-90m-ipo-to-expand-development-of-needle-free-injector-and-pain-drugs/<div class"xn-content"><p><span class"xn-location">SAN DIEGO</span>, <span class"xn-chron">Sept. 7</span> /PRNewswire/ -- Zogenix, Inc. ("Zogenix") announced today that it has filed a registration statement with the Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for...Thu, 09 Sep 2010 12:00:00 AM GMThttp://www.pharmatimes.com/Article/10-09-01/Russia_s_Pharmsynthez_plans_%C2%A310_5_million_IPO.aspxPharma Times -- Russia's Pharmsynthez has unveiled plans to float on the Moscow Interbank Currency Exchange (MICEX) to help fund a new facility and international expansion.Wed, 01 Sep 2010 12:00:00 AM GMThttp://www.pehub.com/79198/nupathe-cuts-ipo-price/CONSHOHOCKEN, PA--(Marketwire - 08/06/10) - NuPathe Inc. (NASDAQ:PATH - News), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at $10.00 per share...Fri, 06 Aug 2010 12:00:00 AM GMThttp://www.pehub.com/78986/horizon-pharma-files-for-ipo/NORTHBROOK, Ill.</span>, <span class"xn-chron">Aug. 3</span> /PRNewswire/ -- Horizon Pharma, Inc. announced today that it has filed a registration statement on form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.</p>...Wed, 04 Aug 2010 12:00:00 AM GMThttp://www.businessweek.com/ap/financialnews/D9H7HI380.htmBloomberg -- Development-stage biotechnology company Trius Therapeutics Inc. expects to raise up to $84 million this week in an initial public offering.Wed, 28 Jul 2010 12:00:00 AM GMThttp://www.xconomy.com/san-diego/2010/07/15/trius-ipo-plans-back-on-track/Xconomy -- San Diegos Trius Therapeutics, which was forced to postpone its planned IPO earlier this year to accommodate new FDA guidelines, appears to be back on track. The biotech amended its IPO filing with the Securities and Exchange Commission earlier this week, and the companys stock offering is now on the runway and scheduled for the week of July 26, according to Renaissance Capitals IPO calendar...Thu, 22 Jul 2010 12:00:00 AM GMThttp://www.rttnews.com/Content/BreakingNews.aspx?Node=B1&Id=1361888SAN MATEO, Calif., Jul 16, 2010 (BUSINESS WIRE) -- Epocrates, Inc., a leading provider of mobile drug reference tools and interactive services to healthcare professionals and the healthcare industry, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.</p><p>J.P. Morgan...Mon, 19 Jul 2010 12:00:00 AM GMThttp://www.businessweek.com/news/2010-07-09/preglem-said-to-hire-credit-suisse-for-initial-public-offering.htmlJuly 9 (Bloomberg) -- PregLem SA, a closely held Swiss biotechnology company specialized in womens health, has hired Credit Suisse Group AG for a possible initial public offering, according to two people familiar with the situation.Fri, 09 Jul 2010 12:00:00 AM GMThttp://www.rttnews.com/Content/BreakingNews.aspx?Node=B1&Id=1338650%20&Category=Breaking%20NewsReuters -- Research Pharmaceutical Services Inc filed with U.S. regulators on Friday to raise up to $100 million in an initial public offering of common stock.Mon, 21 Jun 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=183080&full=1PETACH-TIKVA, ISRAEL--(Marketwire - 06/07/10) - Aposense, a world leader in developing diagnostic and therapeutic drugs based on targeting in vivo apoptosis (programmed cell death), today announced the successful completion of the company's Initial Public Offering in the Israeli market. The company's shares will be listed on the Tel Aviv Stock Exchange (TASE) and trade under the symbol APOS beginning...Wed, 16 Jun 2010 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20100521CapitalVue News -- May 14 -- Sichuan Kelun Pharmaceutical, one of the largest manufacturers of intravenous solutions (IV solutions) in the world, plans to issue 60 million A-shares or 25 percent of its enlarged share capital in its initial public offering (IPO), reports China Securities Journal, citing the company's prospectus. Fri, 21 May 2010 12:00:00 AM GMThttp://www.streetinsider.com/IPOs/NuPathe+Inc.+%28PATH%29+Files+$86.25M+IPO/5637564.htmlBusinessweek -- Specialty pharmaceutical company NuPathe Inc., which is developing a patch that treats migraines, on Friday filed for an initial public offering valued at up to $86.3 million.Mon, 17 May 2010 12:00:00 AM GMT